Surface Oncology (NASDAQ:SURF) reported quarterly earnings of $0.13 per share. This is a 135.14 percent increase over losses of $(0.37) per share from the same period last year.
Immatics Granted U.S. Patent Titled ‘Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6664&f=G&l=50&d=PTXT&p=134&S1=20210615&OS=20210615&RS=20210615
